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Background: While the Public Health Agency of Canada notes 19 cases from May 2019 to February 2020 
relating to e-cigarette or vaping product use-associated lung injury (EVALI) in Canada, there are likely 
many more unreported cases, including non-hospitalized and asymptomatic cases. E-cigarette use or va-
ping exposes users to numerous aerosolized chemical species, some of which have proven to be delete-
rious to health. These chemical species can include vitamin E acetate (VEA), flavourants, base / solvents 
(propylene glycol or vegetable glycerin), psychoactive substances, pesticides, endotoxins, metals, and 
pyrolysis by-products from e-cigarette heating coils. 
Objectives: We aim to review current findings related to EVALI from the standpoint of known chemical 
species currently used in vaping products. We specifically examine the toxicological profiles of these 
chemical species and the mechanisms through which they cause lung injury.
Methods: A comprehensive literature search was performed with MEDLINE for EVALI-related human 
studies that were published between January 1, 2010, and May 15, 2020.  This search strategy identified 
832 case reports, case series, clinical trials, and in-vitro laboratory studies.  From this group, 71 records 
were examined in greater detail. 
Results and Conclusions: Although the chemical composition and toxicology of vaping products have 
largely been characterized, the physiological effects of the chemical interactions between various 
constituents of vaping products and the generation of new species remain inconclusive. Given the rapid 
increase in the popularity of vaping and e-cigarettes, there is a need for further research.  Developing 
a comprehensive understanding of the chronic health effects of vaping through randomized controlled 
trials and physiological studies is prudent and necessary to reduce the long-term impacts on users and 
the health care system.
Chemistry Review of Vaping Products and 
Respiratory Injury
Chester Lau1,2, Ran Zhao1, Dilini Vethanayagam2
1 Department of Chemistry, University of Alberta, Edmonton, Alberta
2 Department of Medicine, University of Alberta, Edmonton, Alberta
Corresponding author: dilini@ualberta.ca
Lau, C., Zhao, R. and Vethanayagam, D. (2020) Chemistry Review of 











Vaping devices, including electronic cigarettes 
(e-cigarettes), are often battery-operated devices 
that initiate the act of heating a liquid into a 
vapour, which then condenses into aerosols as 
it travels downstream from the device towards 
the lungs.1 Most devices are composed of a 
battery, a heating element, a mouthpiece, and a 
chamber that contains the liquid solution. Vaping 
is the process of inhaling aerosols generated from 
e-cigarette devices. These devices have become 
highly popularized since their introduction into the 
North American market in 2007.2,3 Since then, they 
have assumed different names, including cig-
a-likes, e-hookahs, electronic delivery systems 
(ENDS), mods, vapes, vape pens, sub-ohms, 
tank systems.1,4 Their success is largely due to 
originally being marketed to traditional cigarette 
smokers as a healthier alternative because 
they expose users to fewer chemical species.4 
Traditional cigarette products contain over 
600 chemical species, which increases to over 
7000 species when heated due to the formation 
of combustion products.5 At least 69 of these 
resultant species are known to cause carcinogenic 
effects. In contrast, electronic liquids (e-liquids 
and e-juices) generally contain fewer chemical 
species overall.6,7 The compositions of different 
e-liquids vary; however, propylene glycol (PG) and/
or vegetable glycerin (VG, glycerol) are typically 
used as the base (solvent) (Figure 1). The chemical 
structures of PG and VG are included because 
they are common structures and frequently found 
in vaping products. These simple structures 
give further insight into the results of this study. 
Readers interested in the structure of other, more 
complex compounds mentioned in this paper 
can find them through a Google image search. 
E-liquids may contain flavouring compounds and 
nicotine.4 E-cigarettes may also be used to deliver 
many additives including tetrahydrocannabinol 
(THC), cannabidiol (CBD), and butane hash oils.4,8,9 
However, unlike cigarettes where the chemical 
composition of different products has been clearly 
established (i.e. acetone, acetic acid, benzene, 
cadmium, carbon monoxide, formaldehyde, 
hexamine, naphthalene and toluene), the chemical 
interactions between the various constituents and 
the toxicological profiles of vaping fluids is not 
fully understood.5,10 
Rates of e-cigarette use are similar across age and 
sex demographics in Canada and the United States 
(US).  Vaping is particularly popular amongst male 
youth and young adults, especially Americans 
who identify as Hispanic or non-Hispanic White 
Caucasian.11-13 Overall, Black and Asian (South 
Asian and Southeast Asian) Americans were the 
least likely to use e-cigarette products. Prevalence 
within these ethnicities, however, did increase 
between 2017 and 2018.13 The 2017 Canadian 
Tobacco, Alcohol and Drugs Survey (CTADS) found 
that 15% (4.6 million) of Canadians aged 15 or older 
have tried vaping at least once in their life, which 
is an increase from 13% (3.9 million) in 2015.14 
According to the 2019 Canadian Tobacco and 
Nicotine Survey, 4.8% of those surveyed reported 
the use of a vaping device in the prior 30-days, a 
growth from 3% in 2017.15 In 2018, 3.2% of US adults 
Figure 1 Structures of Common E-Liquid Bases.  





reported current use of e-cigarettes.12 Friedman 
and Horn found that the prevalence of e-cigarette 
usage did not discriminate between income or 
education levels,16 but a 2018 Swedish study found 
that lower levels of education correlate with use 
of vaping products.17 The variability of findings 
may be due to the different populations surveyed. 
A recommendation for further research into 
prevalence is warranted due to inconsistencies. 
The 2018-2019 Canadian Student Tobacco, 
Alcohol and Drugs Survey found that students 
who vaped within the prior 30 days (with or without 
nicotine) doubled to 20% from 10% in 2016-17.18 In 
2019, 27.5% of US high school students reported 
current use of e-cigarettes, a significant increase 
from 1.5% in 2011.11 A Canadian survey outlining 
the prevalence of vaping among youth between the 
ages of 16 to 19 from 2017 to 2019 showed similar 
findings (Figure 2a, Figure 2b).19 In 2018, this 
significant increase in e-cigarette use caused the 
Food and Drug Administration (FDA) Commissioner 
and the US Surgeon General to declare youth vaping 
an epidemic.20 While some older users switch to 
vaping as an exit strategy for traditional cigarettes, 
the majority of youth users are using the product 
for recreation.15 Sixty-five percent of adolescents 
who tried an e-cigarette product reported that they 
had borrowed, purchased, or shared it with a friend 
or relative.18 This suggests the accessibility of 
vaping products to youth, despite some attempts 
to restrict sales and regulate the advertising of 
Figure 2a Prevalence of vaping 
in Canada and the United 
States from 2017 to 2019. The 
y-axis presents the proportion 
of adolescents (between 16-19 
years old) who reported vaping 
at least once in their lifetime.*
*Adapted from Hammond et al. 
JAMA Pediatr. 2020.21 
Figure 2b Prevalence of vaping 
in Canada and the United 
States from 2017 to 2019. The 
y-axis presents the proportion 
of adolescents (between 16-19 
years old) who reported vaping 
within the prior 30 days.*
*Adapted from Hammond et al. 
JAMA Pediatr. 2020.21 





such products in Canada and the US. The upward 
trend on e-cigarette usage among youth in 
Canada and the US is associated with the rising 
popularity of products that contain nicotine salts.19 
Nicotine salts allow e-cigarette devices to deliver 
nicotine more efficiently than freebase nicotine 
solutions, adding to the addictive potential 
of e-cigarette products.4 In turn, this greater 
exposure can ultimately lead to detrimental health 
consequences. 
Between July and August 2019, the Centers for 
Disease Control and Prevention (CDC) detailed 
the first reported cases of electronic-cigarette 
or vaping product use-associated lung injury 
(EVALI), resulting in numerous media articles 
in both Canada and the US.8 Soon after the 
beginning of the outbreak, the CDC began to 
use the “EVALI” acronym as a way to report this 
public health crisis.21,22 As of April 7, 2020, there 
have been 19 cases of EVALI reported to the 
Public Health Agency of Canada, including 6 in 
Quebec, 5 in British Columbia, 4 in Ontario, 2 in 
New Brunswick, and 1 case each in Alberta and 
Newfoundland and Labrador.10 As of February 18, 
2020, 2807 probable and confirmed EVALI cases 
were reported to the CDC in the US.6  Sixty-eight of 
these cases resulted in death.6 The demographics 
of US hospitalized patients were similar to those 
of e-cigarette users, mostly of the male sex (66%), 
and non-Hispanic White Caucasians (61%).6,23 
Eighty-two percent of US patients reported the 
use of any THC-containing products and 33% 
reported exclusive use.6 Fifty-seven percent of 
patients reported any use of nicotine-containing 
products, and 14% exclusive use.6 The duration of 
symptoms before presentation to the emergency 
department (ED) and length of hospitalization 
varied from 0 to 155 days and 1 to 120 days, 
respectively.8,24–27 Individuals who actively vape 
can present with respiratory, gastrointestinal 
and constitutional symptoms; however, some 
patients may appear asymptomatic. Laboratory 
analyses in individuals who were actively vaping 
include bloodwork (complete blood counts 
and non-specific inflammatory markers such as 
C-reactive protein), along with chest imaging (chest 
radiography or computerized tomography [CT]). If 
bronchoscopy was performed, a bronchoalveolar 
lavage (BAL) fluid sample was often collected 
for analysis. Aggregated case studies described 
183 subjects of which just over half (53%) were 
admitted into the intensive care unit (ICU).8,24-
27 A majority of the patients showed clinical 
improvement from treatment with glucocorticoids 
and antibiotics.8,24–27 The median age of EVALI-
related death was higher than the median age 
of hospitalization (49.5 years versus 24 years, 
respectively).6 However, the age of death (15 to 75 
years) was similar to hospitalized cases (13 to 85 
years). Pre-existing medical conditions, obesity, and 
simultaneous use of combustible cigarettes while 
vaping appear to increase the risk of EVALI-related 
death.23 Delayed treatment due to an incomplete 
exposure history may exacerbate the severity of 
the illness, leading to death.23 The illicit nature of 
THC products can lead to incomplete exposure 
history. Consequently, it is critical for clinicians to 
nonjudgmentally and privately communicate with 
patients to ensure truthful disclosure.23,28 Despite 
the fall in the number of cases since the peak of the 
outbreak in September 2019, the number of cases 
has not fallen back down to pre-June 2019 levels.29 
Therefore, further research is necessary to establish 
causal relationships between EVALI and specific 
chemical products / compounds of interest.29,30
While many questions regarding the EVALI outbreak 
remain, laboratory analysis completed by the FDA 
have established a link to vitamin E acetate (VEA 
or alpha-tocopherol acetate).9,31 VEA is commonly 
found in dietary supplements and dermatologic 
products. It is marketed as being safe for oral 
and topical intake, but it cannot be assumed that 
VEA has no adverse effects when inhaled.4,9 In two 
separate studies, Blount and colleagues detected 
VEA present in 100% and 94% of BAL fluid samples 
of EVALI patients, respectively.9,32 A 2019 study in 
Wisconsin, led by Pray et al., also detected VEA in 
all five THC cartridges belonging to two patients, 





and in available BAL fluid in two patients.31 All eight 
patients interviewed admitted to the use of THC-
containing e-cigarette products and to acquiring 
the products from the illicit market.31 Minnesota 
law enforcement seizures suggests VEA was 
introduced first into illicit products sometime in 
2019 as a cost cutting measure, matching the 
timelines of the EVALI outbreak.9,33 Significantly, 
the findings directly link the outbreak to THC, 
VEA, and illicit e-cigarette products. No causal 
relationship, however, has been established to 
date. EVALI remains a diagnosis of exclusion 
following detailed clinical, radiologic and available 
pathologic and cytopathologic evaluations for 
individual cases.20,34 No clear single assay is 
available for confirmation of diagnosis at this 
time.8,35 We review below, from the perspective 
of chemical agents and toxicology, available 
literature pertaining to EVALI over the prior decade. 
Methods
A literature search for EVALI-related articles was 
completed using MEDLINE, a frequently used 
database for medical and science publications. 
The search was limited to articles published 
between January 1, 2010 and May 15, 2020. Items 
pulled for a more detailed review include cases, 
case studies, clinical trials, and in-vitro laboratory 
studies. Items were excluded if they were a 
duplicate of another article, editorials, reviews, or 
animal studies. The search was further restricted 
to English-language articles only. Additional 
sources were identified through the reference 
section of relevant publications found from the 
literature search. Other primary references were 
obtained from official government websites 
(Health Canada and CDC).
A total of 71 articles were retrieved from our search 
strategy and reviewed, many of which were case 
reports (n=20) and case series (n=7). Five small 
prospective clinical trials were also retrieved, 2 
from Belgium, and 1 each from Canada, the US, 
and Sweden. 
Results
Case Reports and Studies:
Twenty-seven of the retrieved papers were case 
reports and case series (Table 1, Table 2).
Randomized Control Trials: 
Five of the retrieved papers were randomized 
control trials (RCTs) (Table 3).
Overview of Potential Causes of EVALI and 
Establishing Toxicological Profiles:
E-cigarette products contain numerous potentially 
harmful chemical compounds, including 
psychoactive compounds (THC, CBD, nicotine), 
flavouring agents, diluents (VEA, medium-chain 
triglycerides [MCTs]), base (PG, VG), pesticides, 
and other contaminants.9,62–64 Detection of these 
chemicals constituents require the separation 
of e-liquid components by employing gas (GC) or 
liquid chromatography (LC). Mass spectrometry 
(MS) techniques, however, have become the primary 
method for detecting e-liquid constituents because 
their sensitivity and selectivity enables them to 
quantify compounds at the ng/mL scale.62,64,65 
Coupling MS with GC or LC creates an additional 
dimension of separation, minimizing interferences. 
In addition to the use of analytical instruments, 
derivatization techniques may be required to 
further increase detection sensitivity for certain 
compounds. For instance, derivatization with 
2,4-dinitrophenylhydrazine (DNPH) or O-(2,3,4,5,6-
Pentafluorobenzyl)hydroxylamine hydrochloride 
(PFBHA) is required prior to instrumental 
detection of carbonyl-containing flavouring 
compounds.63,66–69 Nuclear magnetic resonance 
(NMR) can be used to confirm structural findings.64 
Multi-instrument analyses (with a combination 
of LC/GC-MS, GC/LC and/or NMR) are useful for 
comprehensive detection of e-liquid constituents. 
In the next sections, we discuss the chemistry and 
toxicology of various e-cigarette constituents. 
THC E-Liquids and VEA
Numerous articles hypothesized possible 
mechanisms by which VEA causes physiological 
dysfunction. One study examined the chemical 






Bonilla et al. 
(2019)36
18/M Within two weeks, the patient presented twice with pneumothoraces and reported vaping pre-
ceding to presentation. He was treated and was asymptomatic in his follow-up visit, reported 
that he stopped vaping. 
Deliwala et 
al. (2020)37 
41/M Authors reported a patient case where symptoms occurred immediately after a switch from 
traditional cigarette to vaping products. CT scan showed presence of opacities.
Flower et al. 
(2017)38
33/M While the patient used traditional cigarettes for 10 years, a 3 month vaping exposure resulted 
in respiratory symptoms and CT abnormalities. A lung biopsy was taken and microscopic 
findings were consistent to RB-ILD. A stoppage of vaping led to radiographic improvements. 
Gay et al. 
(2020)39
46/M Case of ELP due to use of cannabis-containing e-cigarettes. CT, X-ray, and lung biopsy 
showed many abnormalities. The analysis of BAL fluid found LLM.
He et al. 
(2017)40
54/M The patient reported smoking cannabis oil for several years and reported respiratory symptoms. 
CT scan showed a nodular “tree in bloom” pattern, and BAL fluid analysis suggested DAH. 
Hureaux et 
al. (2014)41
43/F Case of respiratory toxicity from vaping. The patient was a chronic cigarette smoker and 
switched to e-cigarettes, causing immediate illness. Ceasing e-cigarette use completed 
resolved all symptoms with no treatment. 
Khan et al. 
(2018)42
40/F Case of organizing pneumonia and pulmonary toxicity related to e-cigarette use. The symp-
toms, CT scans, and clinical course were similar to most EVALI cases. 
Landman et 
al. (2020)43
17/M Canadian patient case report that discussed symptoms, blood test results, chest scan 
imaging, biopsy findings, clinical course, and follow up visits at 1, 2, 3 and 4 months after 
discharge. The article included a literature review on relevant case reports and series. 
Lu et al. 
(2020)44
17/M The patient tested positive for cannabinoids. CT scan showed opacities, septal thickening 
and pneumomediastinum. Patient was admitted to ICU, provided supplemental oxygen, and 
treated with antibiotics and steroids.
Matta et al. 
(2020)45
16/M Authors presented a case report of an individual with a 2 year history of daily vaping. They 
reported symptoms matching other EVALI cases, CT findings (abnormal imaging), clinical 
course and treatment (glucocorticoids and antibiotics). 
Marasco et 
al. (2018)46
17/M Authors presented a case of spontaneous pneumomediastinum. The patient reported taking 
a deep inhalation from an e-cigarette immediately prior to symptom onset. Patient was dis-
charged after CT scans showed no further complications.
McCauley et 
al. (2012)47
42/F Case report of a female with a 7 month history of vaping, which corresponded with onset of 
respiratory symptoms. Authors discussed laboratory findings (LLM in BAL fluid), provided 




41/F Authors presented a female case report. The patient reported switching from combustible 
cigarettes to vaping products 4 to 8 weeks prior to ED presentation. Treated with antibiotics 
and steroids, the patient’s condition stabilized and they were discharged. 
Mittal et al. 
(2020)49
53/M Case of chronic vaping that caused TM. This was the first case presented in literature related 




23/M Authors report the first case of EVALI with AEP connected to vaping illicit THC oils. X-ray and 




47/M Authors present a patient with past medical conditions (diabetes and hypertension) , vaping 
(with THC) and traditional cigarette use and presented to ED. Chest X-ray and CT showed 




25/M 25-year old man with worsening symptoms after vaping THC. CT imaging (with abnormal 





20/M AEP related to e-cigarette use. CT scans and symptoms were similar to most EVALI cases. 
The patient was treated with steroids and showed improvement upon follow-up. 
Wilhite et al. 
(2019)54
22/M Authors reported a patient case with DAH and pulmonary embolism. The patient admitted to 




34/F Reported the first EVALI-related death in the US. The patient with prior health conditions and 
concealed vaping an unknown cannabinoid oil to clinicians. She died 25 days after admission 
from deteriorating respiratory functions. 
Note: AEP = acute eosinophilic pneumonia,  BAL = bronchoalveolar, CT = computed tomography, DAH = diffuse alveolar hemor-
rhage, ED= emergency department, ELP = exogenous lipoid pneumonia, LLM = lipid-laden macrophages, PAP = positive airway 
pressure, RB-ILD = respiratory bronchiolitis interstitial lung disease, THC = tetrahydrocannabinol, TM = tracheomalacia.
 Table 1 Summary of 20 case reports identified in literature search






Billa et al. (2020)35 3 Detailed information of 3 adolescents (15M, 16M, 17M) was provided, including early symp-
toms, clinical course, radiographic imaging, and treatment. Also discussed pesticide compo-
nents detected in patients’ e-cigarette products that may explain symptoms.
Blagev et al. 
(2019)24
60 Patients presented with GI (90%), respiratory (98%) and constitutional (88%) symptoms. Majority 
were admitted to ICU (55%), administered antibiotics (90%) and steroids (95%). 10% of patients 
experienced symptom relapse after initial discharge, and most who followed up within two 
weeks still had abnormal CT and pulmonary function tests.
Carroll et al. 
(2020)56
15 Authors presented 15 patients with a mean age of 17.1 years. 13/15 completed bronchoscopy 
and all serum/urine findings were disclosed. Impatient treatment course (glucocorticoids and 
antibiotics) and outpatient follow-up (pulmonary functions testing) was discussed.
Kalininskiy et al. 
(2019)25
12 Patients experienced a combination of GI, respiratory, and/or constitutional symptoms. 11/12 
(92%) of patients reported using THC containing e-cigarette products. 67% of patients were ad-
mitted to ICU. Half of patients who followed up after discharge had resolved past CT abnormali-
ties and normal spirometry.
Layden et al. 
(2020)8
98 A total of 98 patients (48 probable and 50 confirmed cases) from Wisconsin and Illinois was 
used for the case series. Symptom onset was between April and August 2019. The authors 
provided extensive statistics on specific GI, respiratory and gastrointestinal symptoms.
Maddock et al. 
(2019)26
6 Symptoms and clinical findings were like other case series: abnormal chest radiograph scans, 
high CRP counts. The authors identified LLM found in BAL fluid in all patients. When EVALI 
is suspected and all possible infections are excluded, they suggest LLM may be a marker for 
EVALI.
Rao et al. (2020)27 13 Pediatric EVALI cases identified through chart review (92% had THC e-cigarette use). All patients 
had abnormal chest radiographs; glucocorticoid treatment led to clinical improvements.
Note: CRP = C-reactive protein, CT = computed tomography, GI = gastrointestinal, ICU = intensive care unit, LLM = lipid-laden 
macrophages, THC = tetrahydrocannabinol. 
Table 2 Summary of 7 case series identified in literature search
Author N Control Age Summary
Antoniewicz 
et al. (2019)57
17 17 26 ± 3 
years
Two visits - vaping with and without nicotine (49.4% PG/44.4% VG/5% 
ethanol, 19 mg/mL nicotine if added). Participants completed 30 puffs (3 
s for each puff) over 30 minutes. Vaping with nicotine affects pulmonary 
(increased heart rate) and respiratory (airway obstruction) functions.
Boulay et al. 
(2017)58




Experimental (70% PG/30% VG) and placebo sessions involved 20 healthy 
and 10 asthmatic volunteers. Seated participants were to breathe into the 
e-cigarette 3 times per minute, for 1 hour. Respiratory tests (spirometry 




25 25 23 ± 0.4 
years
Participants each took part in three sessions, sham-vaping, and vaping 
with and without nicotine (50% PG/50% VG, nicotine at 3 mg/mL). Every 30 
s, participants inhaled from e-cigarette for 4 s, held the aerosol for 4s, and 
then exhaled for 25 times. Vaping with nicotine causes oxidative stress 











Trial 1: 23 
± 0.4 years; 
Trial 2: not 
mentioned
Participants each took part in three sessions, sham-vaping, and vaping 
with and without nicotine (50% PG/50% VG, nicotine at 3 mg/mL). Serum 
club cell protein-16 increased; transcutaneous oxygen tension decreased 
after vaping. Vaping PG/VG with or without nicotine at high voltages (60 
W) causes pulmonary epithelium injury.
Song et al. 
(2019)61
30 15 21-30 years Healthy, non-smokers were randomly assigned to the intervention (50% 
PG/50% VG) or control group. For 4 weeks, participants had to use the 
e-cigarette device 2 times per day, 20 puffs over a 60 minute time span. 
There was no significant difference in cell counts, cytokines, or gene 
expression after vaping. Urinary PG was correlated with changes in cell 
counts, lymphocyte, and macrophage count for the intervention group.
Note: PG = propylene glycol, VG = vegetable glycerin. 
Table 3 Summary of 5 randomized control trials identified in literature search





structure of VEA (a tocopherol) as an aliphatic 
molecule, containing a polar component and a 
nonpolar tail portion.9 The hydrophobic nature 
of the long tail portion in VEA has the ability 
to penetrate the surfactant layers in the lung, 
which are critical for respiration, and insert 
itself between surfactant phospholipids.70 In 
doing so, phospholipids contained within the 
surfactant undergo a transformation from a gel 
to a crystalline state. Surfactant in the crystalline 
state causes an increase in the surface tension 
of the air-water interface of the lungs, increasing 
the difficulty of lung expansion during respiration. 
VEA is viscous in nature, allowing the compound 
to stay in and affect the lungs for long periods 
of time.3 Another study found the formation of 
a hydrogen-bonded THC/VEA complex as an 
avenue for potential lung injury.71 This heterodimer 
was found in unvaped e-liquids, as well as in 
aerosols of vaped e-liquid mixtures. Significantly, 
this finding demonstrates that VEA in the form of 
THC/VEA complex may be delivered to the site of 
lung damage, although the complex’s significance 
remains under investigation. Lastly, the heating of 
VEA at sufficient temperatures may produce toxic 
ketenes, carcinogenic alkenes, and benzene.72 
These findings were confirmed using analytical 
and theoretical chemistry approaches. Although 
many EVALI cases are associated with VEA in the 
US, no cases in Canada are believed to be linked 
to VEA. This suggests other compounds found in 
e-cigarette products may play a role in causing 
lung injury. While there is a strong association 
between VEA and EVALI, the true mechanisms by 
which VEA causes lung injury continue to remain 
under speculation. 
Nicotine E-Liquids and Bases 
PG and VG (Figure 1) are common nicotine 
e-liquid bases that may cause a toxicological 
effect or indirectly produce certain harmful 
compounds. Jensen et al. observed the formation 
of formaldehyde-containing hemiacetals from 
e-cigarette products at high voltages (5.0 V).73 
Under the right conditions, formaldehyde can 
be a decomposition product of PG.73 Assuming 
inhaling formaldehyde-releasing agents carries 
the same health risks as gaseous formaldehyde, 
Jensen et al. calculated the lifetime cancer risk 
to be between 5 to 15 times as high as the risk 
associated with long-term combustible cigarette 
use.73 While long-term formaldehyde exposure 
is carcinogenic, acute exposure can irritate 
various mucous membranes, including the upper 
respiratory tract and eyes.74 A similar study by the 
same authors found that pyrolysis of PG and VG 
created toxic organic compounds.75 Corresponding 
compounds that may be generated from vaping 
pyrolysis of PG include acetaldehyde, acetic acid, 
acetone, acrolein, formaldehyde, formic acid, 
hydroxyacetone, lactaldehyde, prop-1-en-1-ol, and 
propanal. On the other hand, VG vaping pyrolysis 
by-products include acetaldehyde, acetic acid, 
acrolein, dihydroxyacetone, formaldehyde, formic 
acid, glyceraldehyde, glycidol, glycolaldehyde, 
and hydroxyacetone. Many of the mentioned 
compounds are considered to be volatile and 
present many inhalation health risks, such as 
irritation and difficulty breathing. The extent of 
pyrolysis by-product formation was dependent 
on the wattage and heat transfer efficiency of the 
e-cigarette device.75 
Flavouring Agents 
Other constituents of concern include 
flavourants, especially diacetyl (2,3-butanedione), 
2,3-pentanedione and acetoin, which are commonly 
found in e-liquids. Like VEA, flavouring compounds 
are safe for digestion, but not inhalation.63 These 
compounds are used by e-liquid manufacturers 
to enhance a product’s flavouring profile.21 The 
addition of flavourants and the use of attractive 
names attract both young adults and adolescents 
to use e-cigarette products. In May 2002, factory 
workers at a microwave popcorn-processing plant 
were diagnosed with bronchiolitis obliterans, also 
known as “popcorn lungs” (see Appendix A).63 Later, 
federal investigations found a direct correlation 
between pulmonary dysfunctions, bronchiolitis 
obliterans, and butter-flavoured compounds used 





in the facility, namely, diacetyl, 2,3-pentanedione, 
and acetoin. These compounds were found 
in 47 of 51 flavoured e-cigarette products 
tested by Allen et al.63 Moreover, a chemical 
investigation showed acetoin slowly converting 
to diacetyl over time when stored in a sealed 
e-cigarette cartridge.66 Conversion rates depend 
on numerous factors, including light exposure, 
ratio of PG/VG, pH, storage length, and amount 
of nicotine. Although occupational exposure 
limits are established for flavouring agents, 
there are no standards for general exposure. 
These occupational limits are particularly not 
applicable to youth, who are more vulnerable 
to exposures.27 Diacetyl and 2,3-pentanedione 
downregulates the expression of genes crucial for 
cilia biogenesis (see Appendix A), and decreases 
the number of ciliated cells.76 Overall, genetic 
material important for cytoskeletal and cilia 
processes are disturbed. Human airway epithelial 
cells (see Appendix A) exposed to e-cigarette 
vapours secrete proinflammatory cytokines (IL-6 
and IL-8) (see Appendix A).77 In a separate study 
on pulmonary epithelial cells, diacetyl exposure 
increased keratin 5 (Kr5) (see Appendix A) protein 
ubiquitination (see Appendix A), and decreased in 
ΔNp63 (see Appendix A) cell marker expression, 
which can potentially reduce airway basal cells’ 
proliferative capacity.78 At diacetyl concentrations 
below 50 mM over one hour, basal cells were able 
to recover and maintain cellular integrity without 
undergoing major damage or death.78
Many studies have tested the physiological 
consequences from vaping exposure of other 
flavouring constituents. In a study from 2016-2017, 
there were over 15000 distinct flavours of e-liquids 
sold online, nearly double the number available in 
2013-2014.77 Cinnamon roll flavoured e-cigarette 
stimulated a far more significant increase in IL-8 
than the other commercial e-liquids tested. In a 
study of cinnamon flavoured e-liquid products, 
cinnamaldehyde, 2-methoxycinnamaldehyde, 
dipropylene glycol, and vanillin were detected.79 
Inhalation of vanillin (or ethyl vanillin) may cause 
respiratory irritation and inflammation.80 This is 
supported by Gerloff and colleagues’ findings, 
who found that vanilin exposure to respiratory 
epithelium caused IL-8 release in human bronchial 
epithelium (Beas2B).81 Moreover, it has been 
suggested that the pyrolysis of vanillin may lead 
to the formation of organic by-products, but this 
has to be assessed in vaping contexts. In the 2016 
study, Behar and colleagues detected cytotoxic 
levels of cinnamaldehyde in 20 out of 39 different 
cinnamon-flavoured e-cigarette products.82 
Cinnamaldehyde caused the depolymerization of 
microtubules within human pulmonary fibroblasts 
(see Appendix A). Additionally, lung cell exposure 
to cinnamaldehyde caused decreased growth, 
changed morphology and motility of cells, and 
increased breakage of DNA strands, leading to 
cell death. Kavvalakis et al.’s study of 263 e-liquid 
samples detected 2,5-dimethylpyrazine (chocolate 
flavour) and 3,4-dimethoxybenzaldehyde (cherry 
flavour) in 5 of 7 brands analyzed.83 Respiratory 
epithelial cell exposure to 2,5-dimethylpyrazine 
activated the cystic fibrosis transmembrane 
conductance regulator (CFTR) ion channel, which 
in turn may compromise pulmonary epithelium 
salt and water homeostasis.84 The toxicology of 
3,4-dimethoxybenzaldehyde have not yet been 
assessed. Tierney et al.’s analysis found that 
maltol (cotton candy and caramel flavour) and 
ethyl maltol (caramel flavour) were detected in 8 
and 9 out of 30 e-liquid products, respectively.85 
Out of all flavouring compounds tested by Hua 
and colleagues using 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
(which assesses cell metabolic activity), they 
found maltol to be the most cytotoxic.86 Besides 
the detection of menthol and menthone in mint-
flavoured e-cigarette products, pulegone was often 
detected in substantial concentrations.87 Pulegone 
is carcinogenic and was banned by the FDA as a 
food additive in 2018. When inhaled, menthol itself 
may cause oxidative stress (see Appendix A), 
inflammation, and dysfunctional cell barriers.80





E-liquid flavouring compounds may also 
react to form other compounds of varying 
toxicological profiles. Farsalinos and Voudris’s 
study confirmed that the heating of flavoured 
e-liquids within an e-cigarette device contribute 
to aldehyde emissions (formaldehyde, acrolein, 
and acetaldehyde), to a minimal, but detectable 
extent.68 Their findings were confirmed in a pilot 
study involving human participants, which found 
aldehyde emissions were higher in exhaled 
flavoured e-cigarette breaths than in pre-
exposed, regular breaths.88 Aldehyde emission is 
exponentially proportional to flavouring compound 
concentrations within e-liquids.89 Moreover, 
lower nicotine concentrations and adjustable 
power settings directly increase acetaldehyde 
and formaldehyde production.90 Muthumalage 
et al. and Gerloff et al. confirmed lung cell 
exposure to flavoured e-liquids lead to increased 
oxidative stress, reduced pulmonary epithelium 
barrier function and caused proinflammatory 
responses.81,91 Certain flavourants may interact 
with PG to form flavourant-PG acetals, which 
suggests the volatility of e-cigarette constituents 
immediately after mixing.92 These flavourant-PG 
acetals are highly stable, persisting in e-cigarette 
users after inhalation, and activating aldehyde-
sensitive TRPA1 and aldehyde-insensitive TRPV1 
irritant receptors (see Appendix A). These 
receptors, through increasing irritation sensation, 
contribute to chronic pulmonary conditions which 
include asthma.92 Lastly, flavouring compounds 
may influence the formation of free radicals in 
aerosolized e-liquids.93 Reactive free radicals 
can induce oxidative stress, damaging crucial 
cell pathways. Other less common chemical 
compounds with the potential to cause injury 
include α or β damascenone (rose-scented), 
3-methyl-1,2-cyclopentanedione (coffee flavour), 
acetamide, linalool, terpineol, citral, corylon 
(caramel flavour), anisaldehyde, trimethylpyrazine, 
eugenol, and limonene (citrus flavour).80,94 
Limonene, in particular, was detectable in illicit 
products and was found in BAL fluid of an EVALI 
patient.32
Other Constituents of Interest 
In a comprehensive analysis of illicit, commercial, 
and medical-grade e-cigarette cartridges, 
Muthumalage et al. reported the detection of 
other potentially harmful compounds in e-liquids, 
including isoprene, acetaldehyde, ethylbenzene, 
toluene, acrolein, 1,3-butadiene, and benzene.62 
The FDA lists these compounds as respiratory 
and cardiac toxicants. Many organic compounds 
detected in e-liquids may explain EVALI patient 
symptoms. For example, the inhalation of acetone 
and 1,2-dichloroethane can cause drowsiness. 
Inhalation of xylenes, and 1,3-pentadiene may 
cause dyspnea (shortness of breath) and chest 
tightness, while 1,3-butadiene can form peroxides 
when exposed to oxygen.62 Furthermore, exposure 
to methyl vinyl ketone and allyl chloride can lead 
to emphysema and edema. Muthumalage and 
colleagues’ detection of pesticides in e-cigarette 
products confirm the findings of other studies.35,62,64 
Tebuconazole, an antifungal agent, was one of 
many pesticides detected in THC-containing 
products that belonged to an EVALI patient.35 
While tebuconazole is not a pulmonary toxicant in 
itself, when heated above 150°C, it decomposes 
into hydrogen chloride (HCl) gas and nitrogen 
oxides.35 HCl can further breakdown to chlorine 
gas (Cl2) which can cause burning sensations in 
the lungs. Nitrogen oxides are pulmonary toxicants 
that can cause respiratory, gastrointestinal, and 
constitutional symptoms experienced by EVALI 
patients. Moreover, elements including silicon, 
copper, nickel, and lead were detected in illicit, 
counterfeit products.62 Although variable, metal 
concentration reached up to 600 ppm in e-liquids. 
Other metals can also be found in e-liquids, 
including chromium, manganese, aluminum, tin, 
iron and cadmium.27 These detected metals may 
be due to the sloughing of the metal heating coil 
within e-cigarette devices due to use over time.95 
Significantly, among Rao and colleagues’ cohort of 
13 patients, the sickest patient’s e-liquid cartridge 
tested positive for cadmium, while all other metals 
tested negative.27 Cadmium potentially causes 
respiratory dysfunction.95 Inhalation of other 





mentioned metals may cause adverse neurologic, 
carcinogenic, respiratory, and cardiovascular 
effects.95 All of these findings suggest EVALI is not 
singularly caused by VEA, but by a combination 
of VEA and other toxic substances in e-cigarette 
products. The CDC currently warns individuals 
against using informally acquired THC-containing 
e-cigarette products.31
Discussion and Conclusion
While e-cigarette products are marketed as being 
the “safer” alternative to traditional combustible 
cigarettes, it does not equate to being “safe” for 
use, especially after the large EVALI outbreak 
in the summer of 2019. The large outbreak 
suggests the heterogeneous nature of e-liquids 
and raises further questions regarding the 
safety of longstanding e-cigarette use. Many 
compounds found in e-liquids are potential 
pulmonary toxicants when inhaled. Products 
obtained by unlawful means often contain more 
compounds harmful to health, an outcome of 
cost-cutting to maximize profit, with a disregard 
to product safety. In doing so, certain premium 
compounds are replaced with cheaper ones, 
but still allow for a similar user experience. A 
lack of regulatory accountability during the 
e-liquid production process may also lead to 
the addition of endotoxins, bacteria, high metal 
content, and organic compounds uncommonly 
found in products for human consumption. 
Endotoxins can lead to the destabilization of 
respiratory immune-regulated disorders, such 
as asthma. Vaping chemistry, through pyrolysis 
and interactions between chemical species, 
further introduces new compounds of varying 
toxicological profiles to the user, many of which 
are harmful. Moreover, free radical reactions 
occurring amongst e-liquid constituents can give 
rise to reactive intermediates, which contribute 
to oxidative stress and adverse health effects. 
Chemical complexation and bonding interactions 
between e-liquid constituents may contribute to 
harm but have not been assessed physiologically. 
Therefore, e-cigarettes are a health risk to 
consumers, of which adolescents and young 
adults are especially vulnerable, who are now the 
primary marketing targets of e-cigarette product 
manufacturers.
VEA remains a strong culprit for EVALI but more 
research is necessary to fully establish causal 
relationships, including the possibility of the injury 
being caused by multiple toxicants. As the lack 
of diagnostic tests further challenges clinicians 
when diagnosing patients with EVALI, there is 
a dire need for assessments of the toxicology 
and carcinogenicity of e-liquid components. In 
particular, from the list of EVALI-related case 
reports and case series summarized in this article 
(Table 1, Table 2), it is clear that the current 
clinical cases can only track down patients with 
acute symptoms that have obvious links to vaping 
practices. Clinical cases where chronic traditional 
cigarette smokers who fell ill immediately after 
transitioning to vaping products raise further 
concerns concerning vaping safety. The health 
impact of long-term and second-hand vaping 
is essentially unknown. More comprehensive 
chemical analyses of vaping products and their 
emissions would be helpful to reveal species that 
do not cause acute health outcomes but exhibit 
cumulative health impacts over time. 
For research approaches, more RCTs and long-
term studies on vaping should be conducted. Con-
sidering only hospitalized cases were reported, 
there are likely numerous cases that remain un-
reported to public health officials in Canada and 
the US. Therefore, despite a drop in the number of 
EVALI cases in the US and a low number of report-
ed cases in Canada, we must remain vigilant and 
expect the possibility of another outbreak. A better 
understanding of the chemical composition of ap-
proved products available for purchase in Canada 
will allow better regulation of individual products, 
including taxation, minimizing long-term harm to 
the individual users and our health system. 
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Glossary of Terms 
Cilia biogenesis: The synthesis of moving structures (cilia) in the lung that sweep debris and microbes 
from the airway.
Epithelial cells: Specific type of body cells that cover body surfaces, including the skin, and organs.
Fibroblast: Cells that synthesize collagen and the extracellular matrix (ECM), structures that provide 
support to surrounding cells.
Keratin 5 (Krt5): Forms the intermediate filaments in basal epithelial cells that make up the cytoskeleton.
Oxidative Stress: The imbalance between free radical generation and presence of antioxidants in the 
body.
Popcorn lungs: An informal term for bronchiolitis obliterans, the inflammation of the bronchioles.
Proinflammatory cytokines (including IL-6 and IL-8): Signaling proteins that promote inflammation. IL-6 
and IL-8 are a specific type of proinflammatory cytokines. The increase in proinflammatory cytokines in 
the body increases inflammation.
TRPA1 / TRPV1: Specific types of ion channel receptors that senses and responds to irritants.
Ubiquitination: Refers to the ubiquitin-proteasome pathway (UPP), where protein complexes degrade 
damage or unused proteins by proteolysis, a cellular reaction that breaks peptide bonds.
ΔNp63: A cell marker found in airway basal cells. The reduction in ΔNp63 may result in suppression of 
cellular proliferative capacity.
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